Recent Press ReleasesApply07.28.2021PFIZER REPORTS SECOND-QUARTER 2021 RESULTS07.23.2021Pfizer and BioNTech to Provide U.S. Government with an Additional 200 Million Doses of COVID-19 Vaccine to Help Meet Continued Need for Vaccine Supply in the U.S.07.22.2021Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein Degrader ARV-47107.21.2021Pfizer Provides Update on U.S. FDA Review of Abrocitinib and XELJANZ® Filings07.21.2021Pfizer and BioNTech Announce Collaboration With Biovac to Manufacture and Distribute COVID-19 Vaccine Doses Within Africa07.19.2021Valneva and Pfizer Complete Recruitment for Phase 2 Trial of Lyme Disease Vaccine Candidate07.19.2021Pfizer Announces New Investor Relations Leader07.08.2021Collaboration Between Abbvie, Biogen and Pfizer Creates World's Largest Browsable Resource Linking Rare Protein-Coding Genetic Variants to Human Health and Disease06.24.2021Pfizer Declares Third-Quarter 2021 Dividend06.23.2021First Participant Dosed in Pfizer’s Pivotal Phase 3 TALAPRO-3 Combination Study of Talazoparib and Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer (mCSPC)Media ContactsGet to Know UsCompany Fact SheetFeatured StoriesPodcastsPress Kits @Pfizer @Pfizer_Newsby pfizerTweets by pfizer_news
